Large opportunity for innovative heart disease meds in China

Research from industry analyst GlobalData finds that western companies are likely to play an important role in providing new cardiovascular disease (CVD) management options in China.

This includes treatments for conditions such as dyslipidemia and heart failure, with companies including Swiss giant Novartis (NOVN: VX) and German pharma major Bayer (BAYN: DE) likely to benefit from the opportunity.

Noting the preponderance of generics drugmakers in this space in the local market, GlobalData said China would continue to be “heavily reliant on foreign players.”